{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:58:22Z","timestamp":1785866302427,"version":"3.56.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults and is where Vasculogenic Mimicry (VM) was first described. VM enables aggressive cancer cells to independently form blood networks, complicating treatment for patients exhibiting VM. Previous studies linked VE-Cadherin phosphorylation at Y658 to gene expression via Focal Adhesion Kinase (FAK), enhancing the Kaiso\/\u03b2-catenin\/TCF-4 complex associated with VE-Cadherin and thereby promoting VM. Recently, an allosteric HIF-2\u03b1 inhibitor (Belzutifan) was FDA-approved for VHL-associated ccRCCs. In this research, we elucidate the primary causes of VM formation in UM patients with chromosome 3p loss and chromosome 8q gain, identifying VHL, BAP1, and FAK as important factors driving VM and worsening prognosis. These factors promote abnormal activation of HIF-2\u03b1 and VE-Cadherin under basal hypoxic conditions, leading to VM formation. Cytoscan 750k experiments on the MUM 2B cell line reveal a loss of chromosome 3p, where the VHL, BAP1, and CTNNB1 genes are located, and a gain of chromosome 8q (FAK), whereas the MUM 2C cell line shows a gain of chromosome 3p. This provides an outstanding cross-sectional model from patient samples to established cell lines for VM studies. LC-MS experiments demonstrate that VE-Cad\/ENG expression is related to FAK activity in UM cell lines. Finally, using a combination of Belzutifan (HIF-2\u03b1 inhibitor) and FAK inhibitor (FAKi), we observed a significant reduction in UM xenografts. Our results lead us to propose combining Belzutifan and FAKi as a personalized treatment strategy for UM patients. This approach inhibits VM formation and counters the initial hypoxic conditions resulting from chromosome 3p loss and chromosome 8q gain in UM patients, instilling confidence in the potential of this treatment strategy.<\/jats:p>","DOI":"10.1038\/s41418-025-01469-9","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T21:50:47Z","timestamp":1740520247000},"page":"1473-1483","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Chromosomal 3p loss and 8q gain drive vasculogenic mimicry via HIF-2\u03b1 and VE-cadherin activation in uveal melanoma"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9588-4747","authenticated-orcid":false,"given":"Daniel","family":"Delgado-Bellido","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Chacon-Barrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Olmedo-Pelayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Jord\u00e1n Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Gilabert-Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3985-6434","authenticated-orcid":false,"given":"Juan","family":"D\u00edaz-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Garcia-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8468-1998","authenticated-orcid":false,"given":"F. J.","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8400-046X","authenticated-orcid":false,"given":"Enrique","family":"de \u00c1lava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"1469_CR1","doi-asserted-by":"crossref","unstructured":"Wu M, Yavuzyi\u011fito\u011flu S, Brosens E, Ramdas WD, Kili\u00e7 E. Worldwide Incidence of Ocular Melanoma and Correlation With Pigmentation-Related Risk Factors. Investig Ophthalmol Vis Sci. 2023;64:45.","DOI":"10.1167\/iovs.64.13.45"},{"key":"1469_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","volume":"20","author":"RD Carvajal","year":"2023","unstructured":"Carvajal RD, Sacco JJ, Jager MJ, Eschelman DJ, Olofsson Bagge R, Harbour JW, et al. Advances in the clinical management of uveal melanoma. Nat Rev Clin Oncol. 2023;20:99\u2013115.","journal-title":"Nat Rev Clin Oncol"},{"key":"1469_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.trecan.2015.07.009","volume":"1","author":"AC Obenauf","year":"2015","unstructured":"Obenauf AC, Massagu\u00e9 J. Surviving at a Distance: Organ-Specific Metastasis. Trends Cancer. 2015;1:76\u201391.","journal-title":"Trends Cancer"},{"key":"1469_CR4","doi-asserted-by":"crossref","unstructured":"Folberg R, Leach L, Valyi-Nagy K, Lin AY, Apushkin MA, Ai Z, et al. Modeling the behavior of uveal melanoma in the liver. Investig Ophthalmol Vis Sci. 2007;48:2967\u201374.","DOI":"10.1167\/iovs.06-1522"},{"key":"1469_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2022.101041","volume":"90","author":"ES Rantala","year":"2022","unstructured":"Rantala ES, Hernberg MM, Piperno-Neumann S, Grossniklaus HE, Kivel\u00e4 TT. Metastatic uveal melanoma: The final frontier. Prog Retinal Eye Res. 2022;90:101041.","journal-title":"Prog Retinal Eye Res"},{"key":"1469_CR6","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/ceo.14214","volume":"51","author":"H Bai","year":"2023","unstructured":"Bai H, Bosch JJ, Heindl LM. Current management of uveal melanoma: A review. Clin Exp Ophthalmol. 2023;51:484\u201394.","journal-title":"Clin Exp Ophthalmol"},{"key":"1469_CR7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10555-018-9762-9","volume":"37","author":"A Maheshwari","year":"2018","unstructured":"Maheshwari A, Finger PT. Cancers of the eye. Cancer Metastasis Rev. 2018;37:677\u201390.","journal-title":"Cancer Metastasis Rev"},{"key":"1469_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ccell.2019.01.009","volume":"35","author":"X Feng","year":"2019","unstructured":"Feng X, Arang N, Rigiracciolo DC, Lee JS, Yeerna H, Wang Z, et al. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK. Cancer Cell. 2019;35:457\u201372.","journal-title":"Cancer Cell"},{"key":"1469_CR9","first-page":"2578","volume":"63","author":"F Tschentscher","year":"2003","unstructured":"Tschentscher F, H\u00fcsing J, H\u00f6lter T, Kruse E, Dresen IG, J\u00f6ckel KH, et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res. 2003;63:2578\u201384.","journal-title":"Cancer Res"},{"key":"1469_CR10","doi-asserted-by":"crossref","unstructured":"Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern MH, et al. Uveal melanoma. Nat Rev Dis Prim. 2020;6:24.","DOI":"10.1038\/s41572-020-0158-0"},{"key":"1469_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01288-1","volume":"20","author":"X Wei","year":"2021","unstructured":"Wei X, Chen Y, Jiang X, Peng M, Liu Y, Mo Y, et al. Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments. Mol Cancer. 2021;20:7.","journal-title":"Mol Cancer"},{"key":"1469_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13046-021-01926-6","volume":"40","author":"S D\u2019Aguanno","year":"2021","unstructured":"D\u2019Aguanno S, Mallone F, Marenco M, Del Bufalo D, Moramarco A. Hypoxia-dependent drivers of melanoma progression. J Exp Clin Cancer Res. 2021;40:159.","journal-title":"J Exp Clin Cancer Res"},{"key":"1469_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1023\/A:1015591624171","volume":"19","author":"EA Seftor","year":"2002","unstructured":"Seftor EA, Meltzer PS, Kirschmann DA, Pe\u2019er J, Maniotis AJ, Trent JM, et al. Molecular determinants of human uveal melanoma invasion and metastasis. Clin Exp Metastasis. 2002;19:233\u201346.","journal-title":"Clin Exp Metastasis"},{"key":"1469_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10456-016-9500-2","volume":"19","author":"JP Yang","year":"2016","unstructured":"Yang JP, Liao YD, Mai DM, Xie P, Qiang YY, Zheng LS, et al. Tumor vasculogenic mimicry predicts poor prognosis in cancer patients: a meta-analysis. Angiogenesis. 2016;19:191\u2013200.","journal-title":"Angiogenesis"},{"key":"1469_CR15","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0002-9440(10)65173-5","volume":"155","author":"AJ Maniotis","year":"1999","unstructured":"Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LMG, Pe\u2019er J, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry. Am J Pathol. 1999;155:739\u201352.","journal-title":"Am J Pathol"},{"key":"1469_CR16","first-page":"473","volume":"7","author":"MA Warso","year":"2001","unstructured":"Warso MA, Maniotis AJ, Chen X, Majumdar D, Patel MK, Shilkaitis A, et al. Prognostic significance of periodic acid-schiff-positive patterns in primary cutaneous melanoma. Clin Cancer Res. 2001;7:473\u20137.","journal-title":"Clin Cancer Res"},{"key":"1469_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0631-x","volume":"16","author":"D Delgado-Bellido","year":"2017","unstructured":"Delgado-Bellido D, Serrano-Saenz S, Fern\u00e1ndez-Cort\u00e9s M, Oliver FJ. Vasculogenic mimicry signaling revisited: Focus on non-vascular VE-cadherin. Mol Cancer. 2017;16:65.","journal-title":"Mol Cancer"},{"key":"1469_CR18","doi-asserted-by":"publisher","first-page":"9343","DOI":"10.3390\/ijms24119343","volume":"24","author":"D Delgado-Bellido","year":"2023","unstructured":"Delgado-Bellido D, Oliver FJ, Vargas Padilla MV, Lobo-Selma L, Chac\u00f3n-Barrado A, D\u00edaz-Martin J, et al. VE-Cadherin in Cancer-Associated Angiogenesis: A Deceptive Strategy of Blood Vessel Formation. Int J Mol Sci. 2023;24:9343.","journal-title":"Int J Mol Sci"},{"key":"1469_CR19","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3389\/fonc.2019.00803","volume":"9","author":"M Fern\u00e1ndez-Cort\u00e9s","year":"2019","unstructured":"Fern\u00e1ndez-Cort\u00e9s M, Delgado-Bellido D, Javier Oliver F. Vasculogenic mimicry: Become an endothelial cell \u201cBut not so much. Front Oncol. 2019;9:803.","journal-title":"Front Oncol"},{"key":"1469_CR20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41418-018-0125-4","volume":"26","author":"D Delgado-Bellido","year":"2019","unstructured":"Delgado-Bellido D, Fern\u00e1ndez-Cort\u00e9s M, Rodr\u00edguez MI, Serrano-S\u00e1enz S, Carracedo A, Garcia-Diaz A, et al. VE-cadherin promotes vasculogenic mimicry by modulating kaiso-dependent gene expression. Cell Death Differ. 2019;26:348\u201361.","journal-title":"Cell Death Differ"},{"key":"1469_CR21","doi-asserted-by":"crossref","unstructured":"Delgado-Bellido D, Bueno-Galera C, L\u00f3pez-Jim\u00e9nez L, Garcia-Diaz A, Oliver FJ. Endothelial Phosphatase VE-PTP Participates in Vasculogenic Mimicry by Preventing Autophagic Degradation of VE-Cadherin. Front Oncol. 2020;10:18.","DOI":"10.3389\/fonc.2020.00018"},{"key":"1469_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05666-7","volume":"14","author":"D Delgado-Bellido","year":"2023","unstructured":"Delgado-Bellido D, Zamudio-Mart\u00ednez E, Fern\u00e1ndez-Cort\u00e9s M, Herrera-Campos AB, Olmedo-Pelayo J, Perez CJ, et al. VE-Cadherin modulates \u03b2-catenin\/TCF-4 to enhance Vasculogenic Mimicry. Cell Death Dis 2023;14:135.","journal-title":"Cell Death Dis"},{"key":"1469_CR23","doi-asserted-by":"crossref","unstructured":"Wicks EE, Semenza GL. Hypoxia-inducible factors: cancer progression and clinical translation. J Clin Invest. 2022;132:e159839.","DOI":"10.1172\/JCI159839"},{"key":"1469_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrc3844","volume":"15","author":"L Gossage","year":"2015","unstructured":"Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2015;15:55\u201364.","journal-title":"Nat Rev Cancer"},{"key":"1469_CR25","doi-asserted-by":"crossref","unstructured":"Fallah J, Brave MH, Weinstock C, Mehta GU, Bradford D, Gittleman H, et al. FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease\u2013Associated Tumors. Clin Cancer Res. 2022;28:4843\u20138.","DOI":"10.1158\/1078-0432.CCR-22-1054"},{"key":"1469_CR26","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, et al. Belzutifan for Renal Cell Carcinoma in von Hippel\u2013Lindau Disease. N. Engl J Med. 2021;385:2036\u201346.","journal-title":"N. Engl J Med"},{"key":"1469_CR27","doi-asserted-by":"crossref","unstructured":"Choueiri TK, McDermott DF, Merchan J, Bauer TM, Figlin R, Heath EI, et al. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. Lancet Oncol. 2023;24:553\u201362.","DOI":"10.1016\/S1470-2045(23)00097-9"},{"key":"1469_CR28","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","volume":"83","author":"AE Chang","year":"1998","unstructured":"Chang AE, Karnell LH, Menck HR. The national cancer data base report on cutaneous and noncutaneous melanoma: A summary of 84,836 cases from the past decade. Cancer. 1998;83:1664\u201378.","journal-title":"Cancer"},{"key":"1469_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","volume":"101","author":"RD Carvajal","year":"2017","unstructured":"Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: Treatment options and future prospects. Br J Ophthalmol. 2017;101:38\u201344.","journal-title":"Br J Ophthalmol"},{"key":"1469_CR30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41392-023-01362-2","volume":"8","author":"J Hu","year":"2023","unstructured":"Hu J, Tan P, Ishihara M, Bayley NA, Schokrpur S, Reynoso JG, et al. Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma. Signal Transduct Target Ther. 2023;8:155.","journal-title":"Signal Transduct Target Ther"},{"key":"1469_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/onc.2017.338","volume":"37","author":"D Tarade","year":"2018","unstructured":"Tarade D, Ohh M. The HIF and other quandaries in VHL disease. Oncogene. 2018;37:139\u201347.","journal-title":"Oncogene"},{"key":"1469_CR32","doi-asserted-by":"crossref","unstructured":"Wang M, Zhao X, Zhu D, Liu T, Liang X, Liu F, et al. HIF-1\u03b1 promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment. J Exp Clin Cancer Res. 2017;36:60.","DOI":"10.1186\/s13046-017-0533-1"},{"key":"1469_CR33","doi-asserted-by":"crossref","unstructured":"Liu S, Ni C, Zhang D, Sun H, Dong X, Che N, et al. S1PR1 regulates the switch of two angiogenic modes by VE-cadherin phosphorylation in breast cancer. Cell Death Dis. 2019;10:200.","DOI":"10.1038\/s41419-019-1411-x"},{"key":"1469_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112791","volume":"42","author":"IG Cannell","year":"2023","unstructured":"Cannell IG, Sawicka K, Pearsall I, Wild SA, Deighton L, Pearsall SM, et al. FOXC2 promotes vasculogenic mimicry and resistance to anti-angiogenic therapy. Cell Rep. 2023;42:112791.","journal-title":"Cell Rep"},{"key":"1469_CR35","doi-asserted-by":"publisher","first-page":"2407223","DOI":"10.1155\/2022\/2407223","volume":"2022","author":"S Rani","year":"2022","unstructured":"Rani S, Roy S, Singh M, Kaithwas G. Regulation of Transactivation at C-TAD Domain of HIF-1 \u03b1 by Factor-Inhibiting HIF-1 \u03b1 (FIH-1): A Potential Target for Therapeutic Intervention in Cancer. Oxid Med Cell Longev. 2022;2022:2407223.","journal-title":"Oxid Med Cell Longev"},{"key":"1469_CR36","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.cell.2015.09.001","volume":"163","author":"A Serrels","year":"2015","unstructured":"Serrels A, Lund T, Serrels B, Byron A, McPherson RC, Von Kriegsheim A, et al. Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity. Cell. 2015;163:160\u201373.","journal-title":"Cell"},{"key":"1469_CR37","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nature14403","volume":"520","author":"E Wagenblast","year":"2015","unstructured":"Wagenblast E, Soto M, Guti\u00e9rrez-\u00c1ngel S, Hartl CA, Gable AL, Maceli AR, et al. A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature. 2015;520:358\u201362.","journal-title":"Nature"},{"key":"1469_CR38","doi-asserted-by":"crossref","unstructured":"Oraiopoulou ME, Couturier DL, Bunce EV, Cannell IG, Sweeney PW, Naylor H, et al. The in vitro dynamics of pseudo-vascular network formation. Br J Cancer. 2024;131:457\u201367.","DOI":"10.1038\/s41416-024-02722-7"},{"key":"1469_CR39","doi-asserted-by":"publisher","first-page":"8018","DOI":"10.1073\/pnas.131209798","volume":"98","author":"MJC Hendrix","year":"2001","unstructured":"Hendrix MJC, Seftor EA, Meltzer PS, Gardner LMG, Hess AR, Kirschmann DA, et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: Role in vasculogenic mimicry. Proc Natl Acad Sci USA. 2001;98:8018\u201323.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1469_CR40","doi-asserted-by":"crossref","unstructured":"Williamson SC, Metcalf RL, Trapani F, Mohan S, Antonello J, Abbott B, et al. Vasculogenic mimicry in small cell lung cancer. Nat Commun. 2016;7:13322.","DOI":"10.1038\/ncomms13322"},{"key":"1469_CR41","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s12276-023-00979-1","volume":"55","author":"J Kwon","year":"2023","unstructured":"Kwon J, Lee D, Lee SA. BAP1 as a guardian of genome stability: implications in human cancer. Exp Mol Med. 2023;55:745\u201354.","journal-title":"Exp Mol Med"},{"key":"1469_CR42","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.molcel.2019.11.021","volume":"77","author":"S Tamburri","year":"2020","unstructured":"Tamburri S, Lavarone E, Fern\u00e1ndez-P\u00e9rez D, Conway E, Zanotti M, Manganaro D, et al. Histone H2AK119 Mono-Ubiquitination Is Essential for Polycomb-Mediated Transcriptional Repression. Mol Cell. 2020;77:840\u201356.","journal-title":"Mol Cell"},{"key":"1469_CR43","doi-asserted-by":"crossref","unstructured":"Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev Cancer. 2013;13:153\u20139.","DOI":"10.1038\/nrc3459"},{"key":"1469_CR44","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1016\/j.molcel.2021.06.020","volume":"81","author":"E Conway","year":"2021","unstructured":"Conway E, Rossi F, Fernandez-Perez D, Ponzo E, Ferrari KJ, Zanotti M, et al. BAP1 enhances Polycomb repression by counteracting widespread H2AK119ub1 deposition and chromatin condensation. Mol Cell. 2021;81:3526\u201341.","journal-title":"Mol Cell"},{"key":"1469_CR45","doi-asserted-by":"crossref","unstructured":"Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 2000;406:536\u201340.","DOI":"10.1038\/35020115"},{"key":"1469_CR46","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1083\/jcb.201307067","volume":"204","author":"C Jean","year":"2014","unstructured":"Jean C, Chen XL, Nam JO, Tancioni I, Uryu S, Lawson C, et al. Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function. J Cell Biol. 2014;204:247\u201363.","journal-title":"J Cell Biol"},{"key":"1469_CR47","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1158\/0008-5472.CAN-14-1855","volume":"75","author":"CI Schnegg","year":"2015","unstructured":"Schnegg CI, Yang MH, Ghosh SK, Hsu MY. Induction of vasculogenic mimicry overrides VEGF-A silencing and enriches stem-like cancer cells in melanoma. Cancer Res. 2015;75:1682\u201390.","journal-title":"Cancer Res"},{"key":"1469_CR48","doi-asserted-by":"crossref","unstructured":"Puerto-Camacho P, Amaral AT, Lamhamedi-Cherradi SE, Menegaz BA, Castillo-Ecija H, Ord\u00f3\u00f1ez JL, et al. Preclinical efficacy of endoglin-targeting antibody\u2013drug conjugates for the treatment of Ewing sarcoma. Clin Cancer Res. 2019;25:2228\u201340.","DOI":"10.1158\/1078-0432.CCR-18-0936"},{"key":"1469_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03682-z","volume":"12","author":"R Fu","year":"2021","unstructured":"Fu R, Du W, Ding Z, Wang Y, Li Y, Zhu J, et al. HIF-1\u03b1 promoted vasculogenic mimicry formation in lung adenocarcinoma through NRP1 upregulation in the hypoxic tumor microenvironment. Cell Death Dis. 2021;12:394.","journal-title":"Cell Death Dis"},{"key":"1469_CR50","doi-asserted-by":"crossref","unstructured":"Sun D, Sun B, Liu T, Zhao X, Che N, Gu Q, et al. Slug promoted vasculogenic mimicry in hepatocellular carcinoma. J Cell Mol Med. 2013;17:1038\u201347.","DOI":"10.1111\/jcmm.12087"},{"key":"1469_CR51","doi-asserted-by":"publisher","first-page":"e2217840120","DOI":"10.1073\/pnas.2217840120","volume":"120","author":"A Bononi","year":"2023","unstructured":"Bononi A, Wang Q, Zolondick AA, Bai F, Steele-Tanji M, Suarez JS, et al. BAP1 is a novel regulator of HIF-1\u03b1. Proc Natl Acad Sci USA. 2023;120:e2217840120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1469_CR52","doi-asserted-by":"crossref","unstructured":"Chan DA, Giaccia AJ. PHD2 in tumour angiogenesis. Brit J Cancer. 2010;103:1\u20135.","DOI":"10.1038\/sj.bjc.6605682"},{"key":"1469_CR53","doi-asserted-by":"crossref","unstructured":"Nanes BA, Chiasson-MacKenzie C, Lowery AM, Ishiyama N, Faundez V, Ikura M, et al. p120-catenin binding masks an endocytic signal conserved in classical cadherins. J Cell Biol. 2012;199:365\u201380.","DOI":"10.1083\/jcb.201205029"},{"key":"1469_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13312","volume":"7","author":"J Frost","year":"2016","unstructured":"Frost J, Galdeano C, Soares P, Gadd MS, Grzes KM, Ellis L, et al. Potent and selective chemical probe of hypoxic signalling downstream of HIF-\u03b1 hydroxylation via VHL inhibition. Nat Commun. 2016;7:13312.","journal-title":"Nat Commun"},{"key":"1469_CR55","doi-asserted-by":"crossref","unstructured":"Paradis JS, Acosta M, Saddawi-Konefka R, Kishore A, Lubrano S, Gomes FG, et al. Synthetic Lethal Screens Reveal Co-Targeting FAK and MEK as a Multimodal Precision Therapy for GNAQ -Driven Uveal Melanoma. Clin Cancer Res. 2021;27:3190\u2013200.","DOI":"10.1158\/1078-0432.CCR-20-3363"},{"key":"1469_CR56","doi-asserted-by":"publisher","first-page":"11520","DOI":"10.1158\/0008-5472.CAN-05-2468","volume":"65","author":"DWJ Van Der Schaft","year":"2005","unstructured":"Van Der Schaft DWJ, Hillen F, Pauwels P, Kirschmann DA, Castermans K, Oude Egbrink MGA, et al. Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res. 2005;65:11520\u20138.","journal-title":"Cancer Res"},{"key":"1469_CR57","doi-asserted-by":"crossref","unstructured":"Pardali E, Van Der Schaft DWJ, Wiercinska E, Gorter A, Hogendoorn PCW, Griffioen AW, et al. Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma. Oncogene. 2011;30:334\u201345.","DOI":"10.1038\/onc.2010.418"},{"key":"1469_CR58","doi-asserted-by":"crossref","unstructured":"Knowles HJ, Schaefer KL, Dirksen U, Athanasou NA. Hypoxia and hypoglycaemia in Ewing\u2019s sarcoma and osteosarcoma: Regulation and phenotypic effects of Hypoxia-Inducible Factor. BMC Cancer. 2010;10:372.","DOI":"10.1186\/1471-2407-10-372"},{"key":"1469_CR59","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/13543784.2020.1740680","volume":"29","author":"A Mohanty","year":"2020","unstructured":"Mohanty A, Pharaon RR, Nam A, Salgia S, Kulkarni P, Massarelli E. FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials. Expert Opin Investigational Drugs. 2020;29:399\u2013409.","journal-title":"Expert Opin Investigational Drugs"},{"key":"1469_CR60","doi-asserted-by":"crossref","unstructured":"Maxwell PH, Wlesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271\u20135.","DOI":"10.1038\/20459"},{"key":"1469_CR61","doi-asserted-by":"crossref","unstructured":"Kaelin WG. Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer. J Clin Invest. 2022;132:e162480.","DOI":"10.1172\/JCI162480"},{"key":"1469_CR62","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1038\/s41388-020-01616-1","volume":"40","author":"B You","year":"2021","unstructured":"You B, Sun Y, Luo J, Wang K, Liu Q, Fang R, et al. Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR. Oncogene. 2021;40:1674\u201389.","journal-title":"Oncogene"},{"key":"1469_CR63","doi-asserted-by":"crossref","unstructured":"Liu Q, Zhao E, Geng B, Gao S, Yu H, He X, et al. Tumor-associated macrophage-derived exosomes transmitting miR-193a-5p promote the progression of renal cell carcinoma via TIMP2-dependent vasculogenic mimicry. Cell Death Dis. 2022;13:382.","DOI":"10.1038\/s41419-022-04814-9"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01469-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01469-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01469-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T06:47:49Z","timestamp":1757141269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01469-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1469"],"URL":"https:\/\/doi.org\/10.1038\/s41418-025-01469-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4703247\/v1","asserted-by":"object"}]},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"These studies were approved and performed in strict accordance with the recommendations of the Ethic and Research Committee of Virgen del Rocio University Hospital, Seville. The study was conducted by the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of Hospital Universitario Virgen del Roc\u00edo-Instituto de Biomedicina de Sevilla Biobank (Andalusian Public Health System Biobank and ISCIII-Red de Biobancos PT13\/0010\/0056) for studies involving humans. All animal experiments were conducted by protocols and conditions approved by the European guidelines (EU Directive 2010\/63\/EU). Protocols were approved by the local institution and the Direcci\u00f3n General de la Producci\u00f3n Agr\u00edcola y Ganadera de la Junta de Andaluc\u00eda in Spain.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}